Join
Live feed
·
INSIDERFilingvia Quantisnow
Candel Therapeutics Inc. logo

Chief Technology Officer Tyagarajan Seshu sold $70,151 worth of shares (7,000 units at $10.02) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 83,865 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CADL· Candel Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CADL (Candel Therapeutics Inc.) and more on Quantisnow.